|
|
Karolinska Science Park
Fogdevreten 2, Stockholm, S-171 77 Sweden
phone:(46) 70 968 76 01
fax:(46) 8 108 208
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.accuro.net
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| New vaccination and therapy alternatives for cancer and other infectious diseases. |
|
| Management |
| Max Petersson COO, Head of R&D and IP Strategy, VP Human T-cell Research; Per Grufman, VP Murine Research; Peter Wolpert, Chairman |
| |
|
|
| |
|
| Keywords |
| immunology, biomedical, discovery, teipp1, technology, immunotherapies, escape, variants, cancer, AllergyImmunology |
|
|
|
| Description |
|
Based on its proprietary TEIPP1 technology, Accuro develops active immunotherapies directed at escape variants of several cancers. TEIPP technology holds potential for new vaccination and therapy alternatives for cancer, and potentially also for other infectious diseases |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members